Kang, Sujin
Kishimoto, Tadamitsu
Article History
Received: 27 February 2021
Revised: 27 May 2021
Accepted: 28 May 2021
First Online: 12 July 2021
Competing interests
: T.K. holds a patent for tocilizumab and has received royalties for Actemra.